Research Funded

$100,000 to UofL James Graham Brown Cancer Center in 2015

Twisted Pink continued funding to Dr. Yoannis Imbert Fernandez to continue her work with Targeting 6-Phosphofructo-2-Kinase To Increase the Efficacy of ER and CDK4/6 Inhibitors Against Metastatic Breast Cancer

In 2017 Twisted Pink was a founding member of the Metastatic Breast Cancer Research Collective. Together with Hope Scarves and The Cancer Couch Foundation we raised $600,000 and secured an anonymous 1:1 match for each dollar we raised for a total donation of $1.2 million. With these donations we supported two cutting edge research projects:

Memorial Sloan Kettering Cancer Center– Looking specifically at a new class of MBC drugs called CDK 4/6 inhibitors with the tools of DNA and RNA sequencing to understand and overcome resistance mechanisms.

Dana-Farber Cancer Center at Harvard University– Researchers there are working to create a “Resistance Atlas” for ER-positive metastatic breast cancer, which should help inform treatment decisions for individual patients and propel the development of new combination treatment strategies.

Twisted Pink serves as an advocate partner of The MBC Project. This project is providing access to an unprecedented database of genetic information from patients with metastatic breast cancer.

Dr. Yoannis Imbert -Fernandez, Ph.D., University of Louisville, James Graham Brown Cancer Center

$50,000 to support the following research: Targeting Breast Cancer Resistance to Palbociclib via Oncolytic Virotherapy.

A 2 million dollar grant was awarded to Dr. Yoannis Imbert- Fernandez by the National Institutes of Health. This would not have been possible without the support of Twisted Pink to her basic and translational research on metastatic breast cancer.

$150,000 to support the following research: New Therapeutic Targets for Patients with Existing Metastasis.

This research funding is being matched to provide $300,000 towards the project.

$100,000 to support the following research: Phase 1-2 Trial Combining Talimogene Laherparepvec (TVEC) with Pembrolizumab in Metastatic Breast Cancer Patients

This trial was delayed due to COVID-19 and started enrolling patients in July 2021.

$200,000 to support the following research: Strategies to Promote Innate Immune Targeting of Breast Cancer Metastasis

$100,000 was allocated in 2019 and another $100,000 in 2020 after Twisted Pink received a satisfactory update on the project.

This research funding was matched to provide $400,000 towards the project.